

## News Release

December 20, 2019  
Carna Biosciences, Inc.

### **Carna filed CTA in Europe for AS-0871**

Carna Biosciences, a biopharmaceutical company focusing on the discovery and development of innovative drugs targeting kinases, announces today that it has filed a Clinical Trial Application (CTA) with Central Committee on Research Involving Human Subjects (CCMO) in Netherlands for AS-0871, an investigational small molecule drug designed to non-covalently inhibit Bruton's tyrosine kinase (BTK) with high selectivity targeting inflammatory and immune disorders. Carna plans to initiate a phase 1 study in healthy volunteers next year after the completion of the CTA filing process.

"This Clinical Trial Application marks the first important milestone in Carna's history to become a clinical-stage biopharmaceutical company. We expect AS-0871 to enter the Phase 1 study soon, and hope to contribute to the patients who suffer from diseases," said Kohichiro Yoshino, Ph.D., President and Chief Executive Officer at Carna Biosciences.

The CTA does not impact Carna's consolidated financial forecasts for the year ending December 2019.

#### About AS-0871

Bruton's Tyrosine Kinase (BTK) is known to play a crucial role in multiple signaling pathways related to the immune responses in B-cells, macrophages, and mast cells, regulating the release of several proinflammatory mediators. The implication of BTK in a variety of pathological processes has been reported, and thus BTK has emerged as a promising target for inflammatory and immune disorders involving B-cell, macrophage, and mast cell activation. AS-0871 is a highly selective and non-covalent BTK inhibitor discovered by Carna, being developed for the treatment of inflammatory and immune disorders.

#### Contact:

Corporate Planning

Carna Biosciences, Inc.

TEL: +81-78-302-7075

<https://www.carnabio.com/english/>